Maegim한국어

경동제약

011040KOSDAQSector: Pharma & Biotech
₩4,970▲ 0.71%Market cap ₩152.9BAs of Jul 21, 2026 close · updated once daily
B
Grade B64.5 ptsTop 23% of 2,523 stocks
Financial strength
60.7
Growth momentum
52.8
Price attractiveness
77.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

60.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
40.6%
✓ Above median · Top 38.4% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
162.0%
✗ Below median · Top 55.9% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.9%
✓ Above median · Top 31.9% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
3.7%
✓ Above median · Top 31.1% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

52.8
How much did revenue grow in a year?
Revenue growth (YoY)
1.2%
✗ Below median · Top 63.2% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
2.4%
✗ Below median · Top 60.7% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
192.2%
✓ Above median · Top 8.7% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-7.8%
✗ Below median · Top 56.2% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

77.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
17.9x
✓ Above median · Top 24.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.67x
✓ Above median · Top 21.7% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15